SpringWorks Therapeutics (Merck KGaA)
SpringWorks developed nirogacestat, the first approved treatment for desmoid tumours, and mirdametinib for NF1 plexiform neurofibromas; Merck KGaA acquired it in 2025.
Nirogacestat (Ogsiveo, November 2023; DeFi) and mirdametinib (Gomekli, February 2025). Merck KGaA completed the ~$3.9B acquisition in 2025.
Pages like this
not linked directly; found by shared links- TrialDeFi
Shares Nirogacestat, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaMandatory national virtual tumour boards for rare and complex cancers
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaOne legal framework for pooling rare cancer data across borders
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaIntermittent or stop-and-restart nirogacestat in desmoid tumours
- IdeaA funded expert second opinion for every new high-stakes or rare cancer diagnosis
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- IdeaLet adolescents from age 12 into adult trials when the cancer biology is the same
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- TermFNCLCC grade (soft-tissue sarcoma)
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
- PersonTerry Fox
Shares Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).